目的 探討參芍膠囊聯(lián)合鹽酸維拉帕米片治療不穩(wěn)定型心絞痛的臨床療效。方法 選取2018年2月-2019年2月在四川省骨科醫(yī)院治療不穩(wěn)定型心絞痛的患者92例，根據(jù)用藥的差別分為對照組（46例）和治療組（46例）。對照組口服鹽酸維拉帕米片，80 mg/次，3次/d；治療組在對照組的基礎(chǔ)上口服參芍膠囊，4粒/次，2次/d。兩組患者均治療4周。觀察兩組患者臨床療效，同時比較治療前后兩組患者心絞痛發(fā)作次數(shù)和持續(xù)時間，SAQ和GQOLI-74積分，血清C反應(yīng)蛋白（CRP）、白細胞介素-6（IL-6）、髓過氧化物酶（MPO）、妊娠相關(guān)血清蛋白A（PAPP-A）、肌鈣蛋白I（CTnI）和脂蛋白磷脂酶A2（Lp-PLA2）水平，以及全血黏度（WBV）、血漿黏度（PV）、纖維蛋白原（FIB）和血小板黏附率（PAR）水平。結(jié)果 治療后，對照組和治療組臨床有效率分別為82.61%和97.83%，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者心絞痛發(fā)作次數(shù)顯著降低（P<0.05），心絞痛發(fā)作持續(xù)時間顯著縮短（P<0.05），且治療組心絞痛發(fā)作次數(shù)和持續(xù)時間顯著好于對照組（P<0.05）。治療后，兩組患者SAQ積分、GQOLI-74評分均顯著升高（P<0.05），且治療組QRS和GQOLI-74積分顯著高于對照組（P<0.05）。治療后，兩組患者血清CRP、IL-6、MPO、PAPP-A、CTnI、Lp-PLA2水平均明顯降低（P<0.05），且治療組上述血清學(xué)指標顯著低于對照組（P<0.05）。治療后，兩組患者WBV、PV、FIB、PAR水平均顯著降低（P<0.05），且治療后治療組WBV、PV、FIB、PAR水平明顯低于對照組（P<0.05）。結(jié)論 參芍膠囊聯(lián)合鹽酸維拉帕米片治療不穩(wěn)定型心絞痛可明顯改善患者臨床癥狀，降低血清CRP、IL-6、MPO、PAPP-A、CTnI、Lp-PLA2水平，促進生活質(zhì)量的改善。

Objective To explore the clinical efficacy of Shenshao Capsules combined with verapamil intreatment of unstable angina pectoris. Methods Patients (92 cases) with unstable angina pectoris in Sichuan Province Orthopaedic Hospital from February 2018 to February 2019 were divided into control (46 cases) and treatment (46 cases) groups based on different treatments. Patients in the control group were po administered with Verapamil Hydrochloride Tablets, 80 mg/time, three times daily. Patients in the treatment group were po administered with Shenshao Capsules on the basis of the control group, 4 grains/time, twice daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the frequency and duration of angina pectoris, the SAQ and GQOLI-74 scores, the serum levels of CRP, IL-6, MPO, PAPP-A, CTnI, and Lp-PLA2, and the WBV, PV, FIB, and PAR levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 82.61% and 97.83%, respectively, and there were differences between two groups (P<0.05). After treatment, the frequency of angina pectoris in two groups was significantly decreased (P<0.05), and the duration of angina pectoris was significantly shorten (P<0.05), and the frequency and duration of angina pectoris in the treatment group was significantly better than that in the control group (P<0.05). After treatment, the SAQ and GQOLI-74 scores in two groups were significantly increased (P<0.05), and these scores in the treatment group were significantly higher than those in the control group (P<0.05). After treatment, the serum levels of CRP, IL-6, MPO, PAPP-A, CTnI, and Lp-PLA2 in two groups were significantly decreased (P<0.05), and these serological indexes in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the WBV, PV FIB, and PAR levels in two groups were significantly decreased (P<0.05), and these indexes in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Shenshao Capsules combined with verapamil in treatment of unstable angina pectoris can significantly improve the clinical symptoms, reduce the expression of CRP, IL-6, MPO, PAPP-A, CTnI, Lp-PLA2, and improve quality of life.

R972